Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Biomechanics of Metastatic Defects in Bone
NCT02109952 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to monitor fracture risk associated with bone tumors in cancer patients. Previous studies from our lab have suggested that it is possible to compute the mechanical strength of bones with tumors using computed tomography (CT) scans, which are like three-dimensional X-ray pictures of the affected bones. The next step in determining the usefulness of this type of strength analysis is to see if we can accurately predict who is at risk for bone fracture and which patients are at high risk of fractures. This non-invasive analysis may help physicians determine the best treatment to reduce the risk of an impending bone fracture in the future.
Conditions Studied
Study Locations (8)
Maryland
- Alvin and Lois Lapidus Cancer Center, Sinai Hospital of Baltimore, Inc — Baltimore
Massachusetts
- Department of Orthopaedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School — Boston
Minnesota
- Department of Orthopaedic Surgery, University of Minnesota Medical Center — Minneapolis
New York
- Department of Orthopedic Surgery, Upstate Medical University — Syracuse
Rhode Island
- Department of Orthopaedic Surgery, Rhode Island Hospital — Providence
Texas
- Section of Orthopaedic Oncology, University of Texas M. D. Anderson Cancer Center — Houston
West Virginia
- Edwards Comprehensive Cancer Center, Marshall University — Huntington
Quebec
- Department of Orthopaedic Surgery, McGill University Health Centre — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2009-01 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109952
The ClinicalTrials.gov registry entry for NCT02109952 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 434 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Cancer Bone appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02109952 reports 8 study locations spanning 8 distinct geographic areas — top geographies include Maryland, Massachusetts, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02109952 about?
NCT02109952 is a clinical study titled "Biomechanics of Metastatic Defects in Bone". The purpose of this study is to monitor fracture risk associated with bone tumors in cancer patients. Previous studies from our lab have suggested that it is possible to compute the mechanical strength of bones with tumors using computed tomography (CT) scans, which are like three-dimensional X-ray...
What is the current status of trial NCT02109952?
This trial is currently active not recruiting. The enrollment target is 245 participants. The study started on 2009-01. Estimated completion is 2025-12-31.
What conditions does trial NCT02109952 study?
This clinical trial studies the following conditions: Cancer Bone, Bone Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02109952?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 434 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02109952 being conducted?
This trial has 8 study locations across Maryland, Massachusetts, Minnesota, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.